TITLE

Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

PUB. DATE
January 2011
SOURCE
BMC Psychiatry;2011, Vol. 11 Issue 1, p168
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents information on an analysis, which examines health care resource utilization from a 24-month observational study of schizophrenics initiated on risperidone long-acting therapy (RLAT). It was concluded that treatment with RLAT may lead to decreased hospitalizations for patients suffering from schizophrenia. The background, methods, results, and conclusions of the analysis, are discussed.
ACCESSION #
67663344

 

Related Articles

  • Changing administration route improves compliance.  // Hospital Formulary;Jan95, Vol. 30 Issue 1, p15 

    Reports that converting hospitalized schizophrenic patients from oral to depot medication can increase compliance with therapeutic regimens and reduce relapse. Use of depot administration in long-term treatment; Contraindications.

  • Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel. Ginsberg, G.; Shani, S.; Lev, B. // PharmacoEconomics;1998, Vol. 13 Issue 2, p231 

    In this study, the benefits and costs of treating schizophrenia with either risperidone or clozapine were examined. The lifetime drug-treatment cost incurred by a patient with schizophrenia in Israel was $US7561 (1996 values) with an initial 6-month trial with risperidone, compared with $US6326...

  • Enfermedad de Gilbert y esquizofrenia. Ramos, R. Molina; Curto, S. Villanueva; Ramos, J. M. Molina // Actas Espanolas de Psiquiatria;may2006, Vol. 34 Issue 3, p206 

    Gilbert's syndrome (idiopathic unconjugated hyperbilirubinemia) is a benign hyperbilirubinemia found in the general population. We report one case in which the exacerbation and remission of hyperbilirubinemia closely correlated with the psychosis of schizophrenia. Some studies have reported that...

  • Clinical status course and quality of life after the first 1 year of treatment: greek results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Touloumis, Charalambos; Drossinos, Vangelis; Kyrana, Maria; Ntzamaras, Kostas; Sventzouri, Fotini; Mavreas, Venetsanos; Novick, Diego // Annals of General Psychiatry;2006 Supplement 1, Vol. 5, pS133 

    A conference paper about the clinical status course and quality of life after the first year of treatment in European patients with schizophrenia is presented. Results reveal that olanzapine-treated patients had higher benefit in overall Clinical Global Impression (CGI) improvements during the...

  • Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. Turkoz, Ibrahim; Bossie, Cynthia A.; Lindenmayer, Jean-Pierre; Schooler, Nina; Canuso, Carla M. // BMC Psychiatry;2011, Vol. 11 Issue 1, p21 

    Background: To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone immediate-release using propensity score methodology. Methods: Six double-blind, randomized, placebo-controlled, short-term clinical trials for acute schizophrenia with availability of...

  • Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Gharabawi, Georges M; Gearhart, Natalie C; Lasser, Robert A; Mahmoud, Ramy A; Young Zhu; Mannaert, Erik; Naessens, Ineke; Bossie, Cynthia A; Kujawa, Mary; Simpson, George M // Annals of General Psychiatry;2007, Vol. 6, p3 

    Background: Several clinical studies have established the efficacy, safety, and tolerability of long-acting risperidone administered once every 2 weeks in patients with schizophrenia or schizoaffective disorder. This report evaluates preliminary efficacy, safety, tolerability, and...

  • Duration of untreated psychosis and clinical outcomes of first-episode schizophrenia: a 4-year follow-up study. Hongyun QIN; Jie ZHANG; Zhenping WANG; Haiying MIN; Caiying YAN; Fuzhen CHEN; Weizhong FU; Ming ZHANG // Shanghai Archives of Psychiatry;Feb2014, Vol. 26 Issue 1, p42 

    Background: The relationship between the duration of untreated psychosis and long-term clinical outcomes remains uncertain. Objective: Prospectively assess the relationship of the duration of untreated psychosis on clinical outcomes in a sample of individuals with first-onset schizophrenia...

  • CONSIDERATION ABOUT TREATMENT NONCOMPLIANCE IN SCHIZOPHRENIA AND HOSPITAL ADDRESSABILITY. BURTEA, V.; IFTENI, P.; CONSTANTIN, D. // Bulletin of the Transilvania University of Brasov, Seriels VI: M;2011, Vol. 4 Issue 1, p67 

    It is estimated that between 26% and 88% of patients with schizophrenia fail to take their medication correctly (1). As it is proposed that the lack or partial non-compliance plays an important role in eliciting the relapse and rehospitalisation, the aim of the current study was to examine the...

  • Schizophrenia treatment deviates from guidelines in Belgium.  // PharmacoEconomics & Outcomes News;4/21/2007, Issue 526, p6 

    The article focuses on a study on the pharmacological treatment of hospitalized schizophrenics in Belgium conducted by M. De Hert, M. Wampers and J. Peuskens published in the December 2006 issue of the "International Journal of Psychiatry in Clinical Practice." According to researchers, there...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics